Thrilled with GOBLET - Positive Data from pancreatic cancer patients in the GOBLET and REO-017 open-label trials showed meaningful improvements in survival
- An ORR of 62% was observed, representing a near tripling from historical controls; 7.2 mo mPFS, 10.6 mo interim mOS are ≥25% compared to historical control trials1-4
- GOBLET data indicate the treatment has been well tolerated with no safety concerns
- Translational data from GOBLET show that patients with increases in blood TILs showed a decrease in tumor volumes
- Registration-enabled study protocol being finalized after pelareorep selected for inclusion by GCAR $5M PanCAN grant to explore pelareorep/mFOLFIRINOX regimen, expecting Q2 2024 start